Abaloparatide
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
ABALOPARATIDE: Drug Repurposing Evaluation Report
One-Sentence Summary
Abaloparatide is a synthetic peptide analog of parathyroid hormone-related protein (PTHrP), approved internationally for the treatment of postmenopausal osteoporosis (marketed as Tymlos® in the US). The TxGNN model has not generated any predicted new indications for this drug, and the evidence pack contains significant data gaps across regulatory, safety, and mechanistic domains.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not listed in Taiwan (no TFDA licenses); internationally approved for postmenopausal osteoporosis |
| Predicted New Indication | — (No TxGNN predictions available) |
| TxGNN Prediction Score | — |
| Evidence Level | N/A — No predictions to evaluate |
| Taiwan Market Status | ✗ Not marketed (未上市) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
There are currently no TxGNN-predicted indications for Abaloparatide, so a mechanistic plausibility assessment cannot be performed at this time.
For background: Abaloparatide is a 34-amino-acid synthetic peptide analog of human parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor in its RG conformation, promoting osteoblast-mediated bone formation while producing a more transient calcemic response compared to teriparatide (PTH 1-34). This anabolic mechanism increases bone mineral density and reduces fracture risk.
Detailed mechanism of action data was not available in this evidence pack (listed as a High-severity data gap). Should TxGNN predictions become available in future iterations, the PTHrP agonist mechanism — with its effects on calcium homeostasis, bone remodeling, and mesenchymal cell signaling — could potentially be relevant to indications beyond osteoporosis.
Clinical Trial Evidence
Currently no TxGNN-predicted indications exist; therefore, no indication-specific clinical trial search was performed.
Literature Evidence
Currently no TxGNN-predicted indications exist; therefore, no indication-specific literature search was performed.
Taiwan Market Information
Abaloparatide has no TFDA-approved licenses and is not marketed in Taiwan. No authorization records are available.
Safety Considerations
Please refer to the package insert for safety information.
Note: TFDA package insert warnings/contraindications were identified as a Blocking-severity data gap (DG001). Drug interaction data was queried but returned no results. Complete safety evaluation cannot proceed until package insert data is obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: There are no TxGNN-predicted new indications for Abaloparatide at this time, and significant data gaps exist across mechanism of action, regulatory, and safety domains. Without a predicted indication, drug repurposing evaluation cannot proceed.
To proceed, the following is needed:
- TxGNN prediction results: Re-run or verify the TxGNN model to determine whether any new indications are predicted for Abaloparatide (DB05084)
- Mechanism of action data (DG002): Query DrugBank API for complete MOA, pharmacodynamic targets, and pathway information
- TFDA package insert (DG001): Obtain and parse the package insert for warnings, contraindications, and prescribing information (if applicable from reference country)
- Regulatory pathway assessment: Since the drug is not marketed in Taiwan, evaluate whether an international reference (e.g., FDA, EMA) approval dossier can be leveraged for any future repurposing application
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.